PunamMalikMD

Pediatric Hematology & Oncology • Cincinnati, OH

Professor, Pediatrics, University of Cincinnati College of Medicine

Join to view full profile

Dr. Malik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Malik's full profile

Already have an account?

Office
3333 Burnet Ave
# 7015
Cincinnati, OH 45229
Phone+1 513-636-4266

Fax+1 513-636-3549

Education & Training

Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 1991 - 1996
Lady Hardinge Medical CollegeClass of 1988

Certifications & Licensure

OH State Medical License 2008 - 2026
CA State Medical License 1996 - 2024
IN State Medical License 2022 - 2023
KY State Medical License 2022 - 2022
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy Start of enrollment: 2005 Dec 01
Terminated
Phase 1
Role of Placenta Growth Factor in Sickle Acute Chest Syndrome Start of enrollment: 2007 Mar 01
Completed
Trial of Zileuton CR in Children and Adults With Sickle Cell Disease Start of enrollment: 2010 Sep 01
Completed
Phase 1
A Phase II Trial of Regadenoson in Sickle Cell Anemia Start of enrollment: 2013 Jul 01
Completed
Phase 2
Gene Transfer for Patients With Sickle Cell Disease Start of enrollment: 2014 Jul 01
Terminated
Phase 1, Phase 2
Screening Patients With Sickle Cell Disease for Kidney Damage Start of enrollment: 2009 Apr 01
Completed
Join now to see all

Publications & Presentations

PubMed

NRASmutation drives elevated angiopoietin-2 expression in human endothelial cells and a genetic mouse model.
Patricia Pastura, C Griffin McDaniel, Sara Alharbi, Dermot Fox, Bethany Coleman
Pediatric Blood & Cancer. 2024-07-01
2 citations
CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model.
Lotus Neidemire-Colley, Shrijan Khanal, Kara M Braunreiter, Yandi Gao, Rathan Kumar
Blood Advances. 2024-02-27
Preclinical safety assessment of modified gamma globin lentiviral vector-mediated autologous hematopoietic stem cell gene therapy for hemoglobinopathies.
Mohammad Shadid, Archana Shrestha, Punam Malik
Plos One. 2024-01-01

Abstracts/Posters

Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric A...
Punam Malik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Progression of Albuminuria in Sickle Cell Anemia: A Multicenter, Longitudinal Study
Punam Malik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Friday Scientific Workshop on Novel Curative Options: Gene-Editing and Gene Therapy for Hemoglobinopathies with a Focus on Sickle Cell Disease
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Disease Modification in Sickle Cell Disease: Mechanisms, Advances and Clinical Implications
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

3 Signs of Progress Against Sickle Cell DiseaseJune 19th, 2019
Early Clinical Trial Data Show Gene Therapy Reversing Sickle Cell AnemiaDecember 3rd, 2018
Ramaswamy's Latest 'Vant' to Focus on Gene Therapies for Blood DisordersNovember 26th, 2018
Join now to see all